Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Blockade of Store-Operated Calcium Entry Reduces IL-17/TNF Cytokine-Induced Inflammatory Response in Human Myoblasts.

Beringer A, Gouriou Y, Lavocat F, Ovize M, Miossec P.

Front Immunol. 2019 Jan 14;9:3170. doi: 10.3389/fimmu.2018.03170. eCollection 2018.

2.

Low incidence of precore W28* mutant variants in treated hepatitis B virus and human immunodeficiency virus co-infected patients.

Boyd A, Lacombe K, Lavocat F, Miailhes P, Lascoux-Combe C, Girard PM, Zoulim F.

Antiviral Res. 2018 Jan;149:174-178. doi: 10.1016/j.antiviral.2017.11.014. Epub 2017 Nov 21.

PMID:
29169914
3.

Early kinetics of serum Interleukine-17A and infarct size in patients with reperfused acute ST-elevated myocardial infarction.

Bochaton T, Mewton N, Thiam N, Lavocat F, Baetz D, Dufay N, Prieur C, Bonnefoy-Cudraz E, Miossec P, Ovize M.

PLoS One. 2017 Nov 22;12(11):e0188202. doi: 10.1371/journal.pone.0188202. eCollection 2017.

4.

Interleukin-25 Produced by Synoviocytes Has Anti-inflammatory Effects by Acting As a Receptor Antagonist for Interleukin-17A Function.

Lavocat F, Ndongo-Thiam N, Miossec P.

Front Immunol. 2017 May 31;8:647. doi: 10.3389/fimmu.2017.00647. eCollection 2017.

5.

Protective effect of low dose intra-articular cadmium on inflammation and joint destruction in arthritis.

Bonaventura P, Courbon G, Lamboux A, Lavocat F, Marotte H, Albarède F, Miossec P.

Sci Rep. 2017 May 25;7(1):2415. doi: 10.1038/s41598-017-02611-5.

6.

T-cell clones from Th1, Th17 or Th1/17 lineages and their signature cytokines have different capacity to activate endothelial cells or synoviocytes.

Lavocat F, Maggi L, Annunziato F, Miossec P.

Cytokine. 2016 Dec;88:241-250. doi: 10.1016/j.cyto.2016.09.019. Epub 2016 Sep 28.

PMID:
27693917
7.

IL-17A and TNF-α Increase the Expression of the Antiapoptotic Adhesion Molecule Amigo-2 in Arthritis Synoviocytes.

Benedetti G, Bonaventura P, Lavocat F, Miossec P.

Front Immunol. 2016 Jun 27;7:254. doi: 10.3389/fimmu.2016.00254. eCollection 2016.

8.

Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients.

Boyd A, Lacombe K, Lavocat F, Maylin S, Miailhes P, Lascoux-Combe C, Delaugerre C, Girard PM, Zoulim F.

J Hepatol. 2016 Oct;65(4):683-691. doi: 10.1016/j.jhep.2016.05.014. Epub 2016 May 19.

PMID:
27210429
9.

Increased sensitivity of rheumatoid synoviocytes to Schnurri-3 expression in TNF-α and IL-17A induced osteoblastic differentiation.

Lavocat F, Osta B, Miossec P.

Bone. 2016 Jun;87:89-96. doi: 10.1016/j.bone.2016.04.008. Epub 2016 Apr 9.

PMID:
27072520
10.

Blockade of bone morphogenetic protein signaling potentiates the pro-inflammatory phenotype induced by interleukin-17 and tumor necrosis factor-α combination in rheumatoid synoviocytes.

Varas A, Valencia J, Lavocat F, Martínez VG, Thiam NN, Hidalgo L, Fernández-Sevilla LM, Sacedón R, Vicente A, Miossec P.

Arthritis Res Ther. 2015 Jul 28;17:192. doi: 10.1186/s13075-015-0710-6.

11.

Differential Effects of IL-17A and TNF-α on Osteoblastic Differentiation of Isolated Synoviocytes and on Bone Explants from Arthritis Patients.

Osta B, Roux JP, Lavocat F, Pierre M, Ndongo-Thiam N, Boivin G, Miossec P.

Front Immunol. 2015 Apr 7;6:151. doi: 10.3389/fimmu.2015.00151. eCollection 2015.

12.

Effects of Interleukin-17A on Osteogenic Differentiation of Isolated Human Mesenchymal Stem Cells.

Osta B, Lavocat F, Eljaafari A, Miossec P.

Front Immunol. 2014 Sep 2;5:425. doi: 10.3389/fimmu.2014.00425. eCollection 2014.

13.

Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy.

Lavocat F, Dény P, Pichoud C, Al Hawajri N, Kitrinos K, Borroto-Esoda K, Zoulim F.

J Hepatol. 2013 Oct;59(4):684-95. doi: 10.1016/j.jhep.2013.05.038. Epub 2013 Jun 3.

PMID:
23742912
14.

High incidence of treatment-induced and vaccine-escape hepatitis B virus mutants among human immunodeficiency virus/hepatitis B-infected patients.

Lacombe K, Boyd A, Lavocat F, Pichoud C, Gozlan J, Miailhes P, Lascoux-Combe C, Vernet G, Girard PM, Zoulim F.

Hepatology. 2013 Sep;58(3):912-22. doi: 10.1002/hep.26374. Epub 2013 Jun 25.

PMID:
23468093
15.

Quantification of hepatitis B e antigen between Elecsys HBeAg and Architect HBeAg assays among patients infected with hepatitis B virus.

Maylin S, Boyd A, Martinot-Peignoux M, Delaugerre C, Bagnard G, Lapalus M, Zoulim F, Lavocat F, Marcellin P, Simon F, Girard PM, Lacombe K.

J Clin Virol. 2013 Apr;56(4):306-11. doi: 10.1016/j.jcv.2012.12.022. Epub 2013 Jan 28.

PMID:
23369885
16.

Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir-based regimen.

Svarovskaia ES, Curtis M, Zhu Y, Borroto-Esoda K, Miller MD, Berg T, Lavocat F, Zoulim F, Kitrinos KM.

J Viral Hepat. 2013 Feb;20(2):131-40. doi: 10.1111/j.1365-2893.2012.01638.x. Epub 2012 Jul 9.

PMID:
23301548
17.

Simvastatin inhibits the pro-inflammatory and pro-thrombotic effects of IL-17 and TNF-α on endothelial cells.

Hot A, Lavocat F, Lenief V, Miossec P.

Ann Rheum Dis. 2013 May;72(5):754-60. doi: 10.1136/annrheumdis-2012-201887. Epub 2012 Aug 21.

PMID:
22915623
18.

Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-hepatitis B virus-infected patients.

Maylin S, Boyd A, Lavocat F, Gozlan J, Lascoux-Combe C, Miailhes P, Lassel L, Delaugerre C, Girard PM, Zoulim F, Lacombe K.

AIDS. 2012 May 15;26(8):939-49. doi: 10.1097/QAD.0b013e328352224d.

PMID:
22333748
19.

Bone marrow-derived and synovium-derived mesenchymal cells promote Th17 cell expansion and activation through caspase 1 activation: contribution to the chronicity of rheumatoid arthritis.

Eljaafari A, Tartelin ML, Aissaoui H, Chevrel G, Osta B, Lavocat F, Miossec P.

Arthritis Rheum. 2012 Jul;64(7):2147-57. doi: 10.1002/art.34391.

20.

Comparison between Elecsys HBsAg II and architect HBsAg QT assays for quantification of hepatitis B surface antigen among patients coinfected with HIV and hepatitis B virus.

Maylin S, Boyd A, Delaugerre C, Zoulim F, Lavocat F, Simon F, Girard PM, Lacombe K.

Clin Vaccine Immunol. 2012 Feb;19(2):242-8. doi: 10.1128/CVI.05454-11. Epub 2011 Dec 21.

21.

Microarray for hepatitis B virus genotyping and detection of 994 mutations along the genome.

Gauthier M, Bonnaud B, Arsac M, Lavocat F, Maisetti J, Kay A, Simon F, Zoulim F, Vernet G.

J Clin Microbiol. 2010 Nov;48(11):4207-15. doi: 10.1128/JCM.00344-10. Epub 2010 Sep 8.

22.

Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection.

Berg T, Marcellin P, Zoulim F, Moller B, Trinh H, Chan S, Suarez E, Lavocat F, Snow-Lampart A, Frederick D, Sorbel J, Borroto-Esoda K, Oldach D, Rousseau F.

Gastroenterology. 2010 Oct;139(4):1207-17. doi: 10.1053/j.gastro.2010.06.053. Epub 2010 Jun 20.

PMID:
20600025
23.

Drug-resistant and immune-escape HBV mutants in HIV-infected hosts.

Lacombe K, Boyd A, Gozlan J, Lavocat F, Girard PM, Zoulim F.

Antivir Ther. 2010;15(3 Pt B):493-7. doi: 10.3851/IMP1495. Review.

Supplemental Content

Loading ...
Support Center